Hepatic metastases

Last revised by Yahya Baba on 29 Aug 2023

Hepatic metastases are 18-40 times more common than primary liver tumors 6. Ultrasound, CT, and MRI are helpful in detecting hepatic metastases and evaluation across multiple post-contrast CT series, or MRI pulse sequences are necessary. 

The demographics of patients with liver metastases will mirror that of the underlying primaries. Incidence, therefore, increases with age.

Liver metastases are usually asymptomatic and found during the workup of a malignancy. If the hepatic metastatic burden is large, then the presentation or symptoms related to the liver disease may include:

  • localized pain and tenderness due to capsular stretching

  • disordered liver metabolic function

  • ascites

  • low-grade fever 2

The most common sites of primary malignancy that metastasize to the liver are 2:

One of the main difficulties in liver imaging for metastatic disease is the high prevalence of benign liver lesions that can be misinterpreted as evidence of metastatic disease, thus dramatically changing a patient's stage, and therefore treatment options. Liver hemangiomas, and to a lesser degree focal nodular hyperplasia (FNH), are the main sources of confusion 3. Additionally, pseudolesions (e.g. transient hepatic attenuation differences (THADs), focal fatty sparing / focal fatty change) may further muddy the waters. Therefore, an understanding of the various appearances of metastatic disease is crucial.

Routine greyscale ultrasound, contrast-enhanced ultrasound, and intra-operative ultrasound all have roles to play.

Unfortunately, not only do metastases have a wide range of appearances, but background echogenicity changes of the liver due to fatty change make absolute statements difficult to make. In general, however, metastases may appear as 3:

  • rounded and well-defined

  • positive mass effect with distortion of adjacent vessels

  • hypoechoic: most common ~65% and is a concerning feature 8

  • hypoechoic halo due to compressed and fat-spared liver

  • cystic, calcified, infiltrative and echogenic appearances are all possible: see liver metastases ultrasound appearances

Contrast-enhanced ultrasound has similar characteristics to CT, able to distinguish between hypovascular liver lesions, and hypervascular liver lesions.

See also: ultrasound appearance of hepatic metastases.

Liver metastases are typically hypoattenuating on unenhanced CT, enhancing less than surrounding liver following contrast 1. If there is concomitant hepatic steatosis, then the lesions may be iso- or even slightly hyperattenuating. Enhancement is typically peripheral, and although there may be central filling in, on portal venous phase, the delayed phase will show washout; helpful in distinguishing a metastasis from a hemangioma 1.

Some primaries have a tendency to produce hyper-enhancing metastases, including renal cell carcinoma, thyroid carcinoma, neuroendocrine tumors, etc. (see hypervascular liver lesions).

The appearance of liver metastases on MRI is also variable, but MRI is more sensitive than CT for the detection of liver metastases 5. MRI examination of the liver may involve numerous sequences (see liver MRI protocol), and choice of the gadolinium contrast agent (extracellular contrast agent or Eovist) is an important consideration.

The most frequent appearances are 5:

  • T1: moderately hypointense

  • T2: mildly to moderately hyperintense

  • T1 C+ (Gd): enhancement may be lesional or perilesional (enhancement outside the confines of the T1 delineated lesion) 7

    • small lesions (<1.5 cm) tend to uniformly enhance

    • larger lesions (>1.5 cm) tend to show transient rim enhancement (i.e. with washout); helpful feature in distinguishing a metastasis from a liver hemangioma

    • perilesional enhancement is most commonly seen in colorectal and pancreatic adenocarcinoma metastases 5

  • T1 C+ (Eovist/Primovist):

    • Eovist/Primovist is often useful for detection and confirmation of metastatic disease

    • on the delayed phase, metastatic lesions do not retain any Eovist/Primovist and essentially appear as "holes" in the liver

  • DWI/ADC b600-800: restricted diffusion with ADC values lower than those of the surrounding parenchyma18

Fluid-fluid levels are considered a specific finding for neuroendocrine tumor metastases 9.

The following should be included in the radiology report 17:

  • number, size and location (using the Couinaud classification) of tumor(s)

  • relationship to the main portal pedicles and hepatic veins

  • portal vein patency

  • radiological signs of portal hypertension

  • extrahepatic metastatic disease

Hepatic metastases from colorectal adenocarcinoma can potentially be treated with hepatic metastasectomy, since they may be the only site of metastatic disease. Up to 20% of patients undergoing metastasectomy for this indication remain disease-free 10. Multiple staging systems for disease-free survival after metastasectomy have been proposed and are being refined. One of the more frequently used systems (e.g. "Fong" score) includes variables such as 11:

  • node-negative primary

  • single hepatic metastasis

  • hepatic metastasis size <5 cm

  • CEA <200 ng/mL

  • disease-free interval >1 year

These variables suggest a better metastasectomy disease-free survival.

Transarterial chemotherapy and radioembolization are other options for the treatment of hepatic metastases. MRI-guided adaptive radiation therapy is a new and unique method of liver tumor treatment for both primary and metastatic disease 16.

General differential imaging considerations include:

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Figure 1: gross pathology
    Drag here to reorder.
  • Case 1: colorectal cancer
    Drag here to reorder.
  • Case 2: metastatic cecal adenocarcinoma, polycystic liver and kidney
    Drag here to reorder.
  • Case 3: from lung cancer
    Drag here to reorder.
  • Case 4: dynamic MRI with hepatocyte-specific agent
    Drag here to reorder.
  • Case 5: from prostate cancer
    Drag here to reorder.
  • Case 6: from ovarian cancer
    Drag here to reorder.
  • Case 7: from colorectal cancer
    Drag here to reorder.
  • Case 8: from gastric cancer
    Drag here to reorder.
  • Case 9
    Drag here to reorder.
  • Case 10: from mucinous adenocarcinoma of colon
    Drag here to reorder.
  • Case 11
    Drag here to reorder.
  • Case 12: from GIST tumor
    Drag here to reorder.
  • Case 13: from rectosigmoid carcinoma
    Drag here to reorder.
  • Case 14: from colon cancer PET-CT
    Drag here to reorder.
  • Case 15: from seminoma of testis
    Drag here to reorder.
  • Case 16: extensive from lung carcinoma on PET
    Drag here to reorder.
  • Case 17 : spontaneous rupture
    Drag here to reorder.
  • Case 18: metastatic breast cancer
    Drag here to reorder.
  • Case 19: metastatic sigmoid colon adenocarcinoma
    Drag here to reorder.
  • Case 20: from breast with calcification
    Drag here to reorder.
  • Case 21: from pancreatic ductal adenocarcinoma
    Drag here to reorder.
  • Case 22: from esophagogastric adenocarcinoma
    Drag here to reorder.
  • Case 23: from pancreatic ductal adenocarcinoma
    Drag here to reorder.
  • Case 24: Metastatic rectosigmoid cancer with polycystic kidney and liver disease
    Drag here to reorder.
  • Case 25: atypical metastases
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.